A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques

Vaccine

Volumn 18, Issue 21, 2000, Pages 2250-2256

  Kent, Stephen J ^a   Zhao, Anne ^a   Dale, C Jane ^a   Land, Sally ^b   Boyle, David B ^c   Ramshaw, Ian A ^d  

^a Macfarlane Burnet Ctr Med Research   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c CSIRO   (Australia)

^d Biology and Environment   (Australia)

Author keywords

Cellular immunity; HIV; Vaccine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MACACA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

AIDS VACCINES; ANIMALS; DNA, VIRAL; FOWLPOX VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; INTERFERON TYPE II; MACACA NEMESTRINA; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC;

EID: 0034008624     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00559-9     Document Type: Article

References (17)

1. Finzi D., Hermankova M., Pierson T., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295-1300.
2. Ogg G.S., Jin X., Bonhoeffer S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
3. Eron J.J., Ashby M.A., Giordano M.F., et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet. 348:1996;1547-1551.
4. Rosenberg E.S., Billingsley J.M., Caliendo A.M., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
5. Kalams S.A., Buchbinder S.P., Rosenberg E.S., et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73:1999;6715-6720.
6. Kent S.J., Woodward A., Zhao A. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques. J. Infect. Dis. 176:1997;1188-1197.
7. Excler J.-L., Plotkin S. The prime-boost concept applied to HIV preventative vaccines. AIDS. 11:1997;S127-S137.
8. Clements-Mann M.L., Weinhold K., Matthews T.J., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177:1998;1230-1246. NIAID AIDS Vaccine Evaluation Group.
9. Leong K.H., Ramsay A.J., Boyle D.B., Ramshaw I.A. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J. Virol. 68:1994;8125-8130.
10. Heine H.G., Boyle D.B. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch. Virol. 131:1993;277-292.
11. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188.
12. Cardinal B., Kent S.J. Behavioural effects of simple manipulable environmental enrichment techniques on macaques. Lab. Primate Newsletter. 37:1998;1-4.
13. Benson J., Chougnet C., Robert-Guroff M., et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J. Virol. 72:1998;4170-4182.
14. Ramshaw I.A., Andrew M.E., Phillips S.M., Boyle D.B., Coupar B.E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature. 329:1987;545-546.
15. Kim J.J., Trivedi N.N., Nottingham L.K., et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immun. 28:1998;1089-1103.
16. Pasquini S., Xiang Z., Wang Y., et al. Cytokines and costimulatory molecules as genetic adjuvants. Immun. Cell. Biol. 75:1997;397-401.
17. Cooper D.A., Emery S. Latent reservoirs of HIV infection: flushing with IL-2? Nature Med. 5:1999;611-612.